In November, 79 new cases were added to the Ozempic MDL (Multidistrict Litigation), bringing the total number of filings to over 200 in just the past two months. The MDL now includes more than 1,300 pending cases which reflect the growing number of individuals who are looking for legal action due to negative effects linked [...]

Last week, attorneys representing plaintiffs in the Ozempic lawsuits filed a revised master complaint in the MDL (Multidistrict Litigation). This updated document refines the allegations against the defendants that include Novo Nordisk, with a sharper focus on claims regarding the drug's role. It causes gastrointestinal injuries and other serious side effects. What is a master [...]

As the number of cases in the Ozempic MDL continues to rise, new filings are focusing on the claim that Novo Nordisk purposely minimized the risks of gastroparesis in its marketing. Plaintiffs’ lawyers argue that the company was aware of Ozempic's effects on stomach motility but chose not to update the warning labels, fearing it [...]

The court has scheduled early discovery and motion practice focused on preemption and the adequacy of warning labels in the Ozempic lawsuits. However, the issue of marketing discovery has not been fully addressed, and plaintiffs are now seeking permission to include it at this early stage through a new motion. Plaintiffs argue that marketing discovery [...]